Overview
ABOS market data
Price History
ABOS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.70 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.28 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -509.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.19 – $3.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $184.2M · P/B 1.81 · P/S 127.90.
Company News
Acumen Pharmaceuticals Reports Cash Balance Of $110.2M As Of June 30, 2026, Expected to Cash Runway Into Early 2027Benzinga · Aug 12, 2026, 11:10 AM
Acumen Pharmaceuticals Q2 EPS $(0.45) Misses $(0.34) EstimateBenzinga · Aug 12, 2026, 11:08 AM
8-K filing — Acumen Pharmaceuticals, Inc. (ABOS)SEC EDGAR · Aug 12, 2026, 11:02 AM
Acumen Pharmaceuticals shares are trading lower. The company highlighted enhanced brain delivery program data and early Alzheimer’s disease insights at Alzheimer’s AAIC 2026.Benzinga · Jul 15, 2026, 5:37 PM
Acumen Announces New Findings Presented At AAIC 2026; JCR Collaboration Shows Improved Brain Penetration Of Anti‑Aβo Antibodies Via Transferrin Receptor Delivery In Mouse And Primate ModelsBenzinga · Jul 15, 2026, 11:35 AM
Acumen Pharmaceuticals To Present Data On Three Trials At Alzheimer's Association International Conference 2026Benzinga · Jul 7, 2026, 11:40 AM
Acumen Pharmaceuticals Exercises Option For Development, Production, Commercialization Of Two Candidates To Treat Alzheimer's Disease Through JCR Pharmaceuticals' Blood-Brain Barrier -Penetrating Technology Platform J-Brain CargoBenzinga · Jun 17, 2026, 4:40 PM
Acumen Pharmaceuticals Nominates Two Development Candidates In Its Enhanced Brain Delivery Program For Alzheimer's Disease Treatments, IND Submission Expected In Mid-2027Benzinga · Jun 16, 2026, 11:50 AM